Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on developing therapies for neurodegenerative and metabolic disorders, has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC, effective June 8, 2026. The six-month agreement, valued at US$250,000, includes company profile creation, media distribution, digital community development, news marketing and lead generation campaigns.
Quantum stated that IR Agency LLC is arm’s-length to the company and holds no direct or indirect equity interest in its securities. The engagement is intended to enhance the company's communication with investors and the broader financial community, potentially increasing awareness of its pipeline and progress.
The company is advancing several drug candidates, including Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Quantum also retains a 19.84% ownership stake (as of March 31, 2026) in Unbuzzd Wellness Inc., which markets the OTC version of UNBUZZD™, along with royalty payments of 7% of sales until a total of $250 million is paid, after which the royalty drops to 3% in perpetuity. Quantum retains full rights to develop pharmaceutical and medical formulations of similar products.
This agreement comes as Quantum continues to build its portfolio of biotech solutions for challenging conditions, including neurodegenerative and metabolic disorders and alcohol misuse disorders. The company's focus on innovative therapies positions it in a competitive sector where investor communication can be critical to funding and partnership opportunities.
The news was disseminated via InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides wire-grade press release syndication and editorial distribution to over 5,000 outlets. For more information on Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM.
Quantum BioPharma trades on the NASDAQ under the symbol QNTM and on the CSE under QNTM. The company's commitment to developing first-in-class therapies for unmet medical needs underscores the importance of effective investor relations as it seeks to advance its clinical programs and create shareholder value.
